Spironolactone Lowers Portal Hypertension by Inhibiting Liver Fibrosis, ROCK-2 Activity and Activating NO/PKG Pathway in the Bile-Duct-Ligated Rat

Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension

(2013) James R. Sowers   ANNALS OF INTERNAL MEDICINE

Aldosterone induction of hepatic stellate cell contraction through activation of RhoA/ROCK-2 signaling pathway

(2011) Hongli Ji et al.   REGULATORY PEPTIDES

Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet

(2010) Tsutomu Wada et al.   ENDOCRINOLOGY

Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis

(2010) Puneeta Tandon et al.   JOURNAL OF HEPATOLOGY

New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis

(2010) Yan Wang et al.   JOURNAL OF HEPATOLOGY

Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis

(2010) Martin Hennenberg et al.   LABORATORY INVESTIGATION

Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice

(2008) Jun Yu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mechanisms of Hepatic Fibrogenesis

(2008) Scott L. Friedman   GASTROENTEROLOGY

Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension

(2008) B Lavina et al.   GUT

Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats

(2008) Vasilica Matei et al.   JOURNAL OF HEPATOLOGY